Drug Trial Radar · NCT01431339
Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Last checked: Nov 19, 2026Latest source record: Feb 12, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
739
Actual
Start
Jul 2011
Primary completion
Nov 2012
Study completion Dec 2012
Sponsor
- Lead sponsor
- Durata Therapeutics Inc., an affiliate of Allergan plcIndustry
- Sponsor type
- Industry
- First posted
- Sep 9, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy) of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral linezolid) for the treatment of patients with a suspected or proved gram-positive bacterial skin or skin structure infections.
Conditions
- Abscess
- Wound Infection
- Surgical Site Infection
- Cellulitis
Interventions
IV DalbavancinDrug
IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8
Vancomycin/LinezolidDrug
IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg every 12 hours). Total duration of therapy is 10-14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Early Clinical EfficacyTime frame: After 48-72 hours of therapy
Locations
137 sites in 14 countries. Site status is shown where the registry gives one.
Durata Clinical Site
Montgomery, Alabama
Durata Clinical Site
Anaheim, California
Durata Clinical Site
Buena Park, California
Durata Study Site
Chula Vista, California
Durata Clinical Site
Long Beach, California
Durata Study Site
Los Angeles, California
Durata Study Site
Norwalk, California
Durata Study Site
Oxnard, California
Durata Study SIte
San Diego, California
Durata Study Site
Stockton, California
Durata Clinical Site
Boyton Beach, Florida
Durata Clinical Site
Fort Meyers, Florida
Durata Clinical Site
Miami, Florida
Durata Study Site
Orlando, Florida
Durata Clinical Site
Saint Cloud, Florida
Durata Clinical Site
Augusta, Georgia
Durata Study Site
Columbus, Georgia
Durata Clinical Site
Chicago, Illinois
Durata Study Site
Baton Rouge, Louisiana
Durata Study Site
New Orleans, Louisiana
Durata Study Site
Shreveport, Louisiana
Durata Study Site
Zachary, Louisiana
Durata Study Site
Las Vegas, Nevada
Durata Study Site
Springfield, Ohio
Durata Study Site
Philadelphia, Pennsylvania
Durata Study Site
Austin, Texas
Durata Clinical Site
Austin, Texas
Durata Clinical Site
Houston, Texas
Durata Study Site
Richmond, Texas
Durata Study Site
Middleton, Wisconsin
Durata Study Site
Pleven, Bulgaria
Durata Study Site
Plovdiv, Bulgaria
Durata Study Site
Sevlievo, Bulgaria
Durata Study Site
Sofia, Bulgaria
Durata Study Site
Sofia, Bulgaria
Durata Study Site
Sofia, Bulgaria
Durata Study Site
Sofia, Bulgaria
Durata Study Site
Kohtla-Järve, Estonia
Durata Clinical Site
Kohtla-Järve, Estonia
Durata Clinical Site
Tallinn, Estonia
Showing 40 of 137 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.